Patients often arrive at this comparison hoping one of the two will turn out to be the gentler or more modern option. That framing does not survive contact with how oncology actually works. These are different tools with different mechanisms, different side effect patterns and different settings, and increasingly they are used together rather than in competition. This article explains the differences clearly so a consultation is easier to follow.
Two Different Mechanisms
Chemotherapy is cytotoxic. It interferes with cell division, which is why it affects abnormal cells strongly and also affects the healthy tissues that divide quickly: bone marrow, hair follicles, and the lining of the mouth and gut. Its effects are consistent enough that they can be anticipated and pre-medicated for.
Immunotherapy is not cytotoxic. It changes immune behaviour, most commonly by blocking the checkpoints that abnormal cells exploit to switch T cells off. The treatment itself does not kill anything. The immune system does, if it engages. A fuller explanation of the mechanism is in what immunotherapy is and how it works.
Immunotherapy vs Chemotherapy at a Glance
| Aspect | Chemotherapy | Immunotherapy |
|---|---|---|
| Mechanism | Directly damages rapidly dividing cells | Changes immune cell behaviour |
| Typical timing of response | Often within weeks | Often slower, response can build over months |
| Common side effects | Nausea, hair loss, low blood counts, infection risk | Fatigue, rash, diarrhoea, hormone gland changes |
| Predictability of side effects | Relatively predictable | Less predictable, can be organ-specific and late |
| Effect after stopping | Usually ends with the drug | Can persist through immune memory |
| Patient selection | Disease type and stage | Disease type, stage and biomarker testing |
| Delivery | Infusion or oral, cyclical | Usually infusion on a repeating cycle |
How the Side Effect Profiles Differ
The common assumption is that immunotherapy is the easier treatment to tolerate. For some people it is. But immune-related reactions can affect the lungs, bowel, liver, heart and hormone glands, and a minority are serious. The difference is not severity so much as character: chemotherapy side effects are broadly expected and time-limited, while immune reactions are variable, organ-specific, and can begin after treatment has finished.
Our detailed guide to immunotherapy side effects and warning signs sets out the warning signs that need same-day assessment.
Speed and Durability of Response
Chemotherapy generally acts faster, which matters when disease needs to be brought under control quickly. Immunotherapy often takes longer because an immune response has to be assembled, and early imaging can be misleading: tissue may appear larger on a scan because immune cells have moved into it, before any improvement is visible.
The other side of that slower start is durability. Where an immune response does establish, it can persist after treatment stops because immune memory does not clear the way a drug does. Neither observation predicts what will happen for any individual.
Why They Are Often Combined
Combination regimens are now standard in several settings rather than a compromise. Chemotherapy can release material from damaged cells that makes the target more visible to the immune system, and it can reduce disease volume while the immune response builds. That complementary timing is the rationale.
Combining does increase the burden of monitoring and the rate of side effects, which is part of the discussion a treating team has before starting.
How the Choice Is Actually Made
- Tissue diagnosis and subtype from the pathology report
- Stage and the extent of spread on imaging
- Biomarker testing, including markers used to predict immune response
- Organ function, particularly liver, kidney, lung and heart
- Autoimmune history and current medication, which can rule out some options
- Previous treatment and how it was tolerated
Which conditions have established immunotherapy indications is covered in conditions treated with immunotherapy.
Where Supportive Care Fits in Bangkok
At MRC Healthcare in Bangkok, patients receiving either treatment sometimes ask about supportive care alongside it. Our position is consistent: the oncology plan set by your treating team is the plan. Anything discussed here sits around it, is documented, and is only proposed after our physicians have reviewed your reports and current medication for interactions.
Where cell-based options such as CIK therapy or NK cell therapy are raised, their investigational status is stated plainly rather than implied, and timing is coordinated so nothing interferes with a treatment cycle already scheduled at home.
For Patients Considering Treatment Abroad
- Never pause or change an oncology regimen to fit a travel plan
- Ask any overseas provider to write to your treating specialist directly
- Confirm what is established treatment and what is investigational
- Check how proposed timing fits between your existing cycles
- Plan the assessment visit separately from any treatment visit
Patients travelling from Australia, Singapore, the United Kingdom, Europe and the Gulf will find the practical steps in our Thailand medical travel checklist.
Get a Clear Answer on Supportive Options
Send your diagnosis and current treatment plan. Our medical team will tell you directly whether anything we offer has a role alongside it, including when the answer is that it does not.
Schedule a Consultation
